文件josephsparano在2019年asco会上发表.pdfVIP

Slide 1 Presented By Joseph Sparano at 2019 ASCO Annual Meeting Background: Rationale for Integrating Genomic and Clinical Risk in Early Breast Cancer Presented By Joseph Sparano at 2019 ASCO Annual Meeting Objectives and Methods: TAILORx Secondary Objective Presented By Joseph Sparano at 2019 ASCO Annual Meeting Slide 4 Presented By Joseph Sparano at 2019 ASCO Annual Meeting Results: Impact of Clinical Risk (CR) on Prognosis by RS Group and Age Presented By Joseph Sparano at 2019 ASCO Annual Meeting Results: Impact of Clinical Risk (CR) on Prediction of Chemotherapy Benefit by Age in RS 11-25 Group (ET vs. Chemo +ET) Presented By Joseph Sparano at 2019 ASCO Annual Meeting Results: Absolute Differences in 9-year Distant Recurrence Rate by Clinical Risk Stratified by Age, RS, and Chemotherapy Use Presented By Joseph Sparano at 2019 ASCO Annual Meeting Slide 8 Presented By Joseph Sparano at 2019 ASCO Annual Meeting Slide 9 Presented By Joseph Sparano at 2019 ASCO Annual Meeting Results: Integrated Risk Assessment in Women 50 Years (N=2958) Presented By Joseph Sparano at 2019 ASCO Annual Meeting Conclusions: Integrating Clinical and Genomic Risk in Breast Cancer to Guide Adjuvant Therapy Presented By Joseph Sparano at 2019 ASCO Annual Meeting Potential Clinical Utility of Integrated RS and Clinical Risk for Guiding Treatment in Women 50 Years Presented By Joseph Sparano at 2019 ASCO Annual Meeting Slide 13 Presented By Joseph Sparano at 2019 ASCO Annual Meeting Acknowledgements Presented By Joseph Sparano at 2019 ASCO Annual Meeting Slide 15 Presented By Joseph Sparano a